title: Comparative study of rapamycin and temsirolimus demonstrates superimposable anti-tumour potency on prostate cancer cells.
abstract: Rapamycin is a macrocyclic lactone currently used for the treatment of cancer and for the prevention of transplant rejection. The primary pharmacological mode of action of rapamycin occurs through the inhibition (blocking) of the mammalian target of rapamycin (mTOR). By doing so, rapamycin interferes with the phosphoinositide 3-kinase (PI3K)-Akt-mTOR axis that controls several cellular functions involving cell growth, proliferation and angiogenesis. The frequent activation of the phosphoinositide 3-kinase (PI3K)/AKT pathway in advanced prostate cancer has provided a rationale for the use of mTOR inhibitors in this setting. We carried out a comparative study on the effects of rapamycin and temsirolimus on the in vitro and in vivo growth of the prostate cancer cell lines, LnCap and PC3. Our results demonstrate that rapamycin and temsirolimus exert similar in vitro and in vivo anti-proliferative effects against prostate cancer cells.
authors: Department of Bio-Medical Sciences, School of Medicine, University of Catania, 95124 Catania, Italy.
authors: Paolo
authors: P
authors: Fagone
authors: Marco
authors: M
authors: Donia
authors: Katia
authors: K
authors: Mangano
authors: Cinzia
authors: C
authors: Quattrocchi
authors: Santa
authors: S
authors: Mammana
authors: Marinella
authors: M
authors: Coco
authors: Massimo
authors: M
authors: Libra
authors: James A
authors: JA
authors: McCubrey
authors: Ferdinando
authors: F
authors: Nicoletti
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D006801:Humans; D008297:Male; D051379:Mice; D009361:Neoplasm Invasiveness; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; C401859:temsirolimus; D020123:Sirolimus